Cargando…

Transcervical extended mediastinal lymphadenectomy for mediastinal restaging after induction therapy

BACKGROUND: The aim of this study was to retrospectively evaluate long-term survival of stage IIIA-N2 non-small cell lung cancer patients operated after induction chemotherapy or chemoradiotherapy and negative mediastinal restaging with transcervical extended mediastinal lymphadenectomy (TEMLA). MET...

Descripción completa

Detalles Bibliográficos
Autores principales: Gwóźdź, Paweł, Zieliński, Marcin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8794284/
https://www.ncbi.nlm.nih.gov/pubmed/35118266
http://dx.doi.org/10.21037/med.2019.09.01
_version_ 1784640794203783168
author Gwóźdź, Paweł
Zieliński, Marcin
author_facet Gwóźdź, Paweł
Zieliński, Marcin
author_sort Gwóźdź, Paweł
collection PubMed
description BACKGROUND: The aim of this study was to retrospectively evaluate long-term survival of stage IIIA-N2 non-small cell lung cancer patients operated after induction chemotherapy or chemoradiotherapy and negative mediastinal restaging with transcervical extended mediastinal lymphadenectomy (TEMLA). METHODS: From January 2007 to December 2013, 48 stage IIIA-N2 non-small cell lung cancer (NSCLC) patients (36 men, 12 women) underwent anatomic pulmonary resection after induction therapy and negative result of mediastinal restaging with TEMLA. Mean age was 58.3 years (range, 46–75 years). There were 28 squamous cell carcinomas, 13 adenocarcinomas, 1 mixed carcinoma and 6 non-small cell lung cancers. Neoadjuvant chemotherapy was given in 24 patients, chemoradiotherapy in 23 and chemotherapy with bradytherapy in 1 patient. All patients were followed-up until death or 60 months since pulmonary resection. RESULTS: There were 29 pneumonectomies, 2 lower bilobectomies and 17 lobectomies. 2 patients had R1 resection. After negative TEMLA, persistent metastatic N2 nodes were discovered in 5 patients (10.4%). The only complication after TEMLA was bilateral vocal cord paralysis observed in 1 patient (2.1%); 2 patients died in early postoperative period due to bronchial fistula (4.2%). Overall 5-year survival of patients operated after negative TEMLA was 39.5%. 5-year survival was not statistically different in patients who underwent lobectomy/bilobectomy and in patients who underwent pneumonectomy (47.4% vs. 34.5%). Five-year survival was lower in patients after chemoradiotherapy than in patients after chemotherapy alone (21.7% vs. 56.0%, P=0.022). 5-year survival was not statistically different in patients with true mediastinal downstaging and in patients with false negative TEMLA (41.9% vs. 20%, P=0.19). CONCLUSIONS: Stage IIIA-N2 non-small cell lung cancer patients who underwent pulmonary resection after induction treatment and negative mediastinal restaging with TEMLA showed good long-term survival. In these patients aggressive surgery, including pneumonectomy, lead to satisfactory outcomes. However, prognosis of patients after induction chemoradiotherapy was worse.
format Online
Article
Text
id pubmed-8794284
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher AME Publishing Company
record_format MEDLINE/PubMed
spelling pubmed-87942842022-02-02 Transcervical extended mediastinal lymphadenectomy for mediastinal restaging after induction therapy Gwóźdź, Paweł Zieliński, Marcin Mediastinum Original Article BACKGROUND: The aim of this study was to retrospectively evaluate long-term survival of stage IIIA-N2 non-small cell lung cancer patients operated after induction chemotherapy or chemoradiotherapy and negative mediastinal restaging with transcervical extended mediastinal lymphadenectomy (TEMLA). METHODS: From January 2007 to December 2013, 48 stage IIIA-N2 non-small cell lung cancer (NSCLC) patients (36 men, 12 women) underwent anatomic pulmonary resection after induction therapy and negative result of mediastinal restaging with TEMLA. Mean age was 58.3 years (range, 46–75 years). There were 28 squamous cell carcinomas, 13 adenocarcinomas, 1 mixed carcinoma and 6 non-small cell lung cancers. Neoadjuvant chemotherapy was given in 24 patients, chemoradiotherapy in 23 and chemotherapy with bradytherapy in 1 patient. All patients were followed-up until death or 60 months since pulmonary resection. RESULTS: There were 29 pneumonectomies, 2 lower bilobectomies and 17 lobectomies. 2 patients had R1 resection. After negative TEMLA, persistent metastatic N2 nodes were discovered in 5 patients (10.4%). The only complication after TEMLA was bilateral vocal cord paralysis observed in 1 patient (2.1%); 2 patients died in early postoperative period due to bronchial fistula (4.2%). Overall 5-year survival of patients operated after negative TEMLA was 39.5%. 5-year survival was not statistically different in patients who underwent lobectomy/bilobectomy and in patients who underwent pneumonectomy (47.4% vs. 34.5%). Five-year survival was lower in patients after chemoradiotherapy than in patients after chemotherapy alone (21.7% vs. 56.0%, P=0.022). 5-year survival was not statistically different in patients with true mediastinal downstaging and in patients with false negative TEMLA (41.9% vs. 20%, P=0.19). CONCLUSIONS: Stage IIIA-N2 non-small cell lung cancer patients who underwent pulmonary resection after induction treatment and negative mediastinal restaging with TEMLA showed good long-term survival. In these patients aggressive surgery, including pneumonectomy, lead to satisfactory outcomes. However, prognosis of patients after induction chemoradiotherapy was worse. AME Publishing Company 2019-09-26 /pmc/articles/PMC8794284/ /pubmed/35118266 http://dx.doi.org/10.21037/med.2019.09.01 Text en 2019 Mediastinum. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0/.
spellingShingle Original Article
Gwóźdź, Paweł
Zieliński, Marcin
Transcervical extended mediastinal lymphadenectomy for mediastinal restaging after induction therapy
title Transcervical extended mediastinal lymphadenectomy for mediastinal restaging after induction therapy
title_full Transcervical extended mediastinal lymphadenectomy for mediastinal restaging after induction therapy
title_fullStr Transcervical extended mediastinal lymphadenectomy for mediastinal restaging after induction therapy
title_full_unstemmed Transcervical extended mediastinal lymphadenectomy for mediastinal restaging after induction therapy
title_short Transcervical extended mediastinal lymphadenectomy for mediastinal restaging after induction therapy
title_sort transcervical extended mediastinal lymphadenectomy for mediastinal restaging after induction therapy
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8794284/
https://www.ncbi.nlm.nih.gov/pubmed/35118266
http://dx.doi.org/10.21037/med.2019.09.01
work_keys_str_mv AT gwozdzpaweł transcervicalextendedmediastinallymphadenectomyformediastinalrestagingafterinductiontherapy
AT zielinskimarcin transcervicalextendedmediastinallymphadenectomyformediastinalrestagingafterinductiontherapy